儿童急性早幼粒细胞白血病的风险适应治疗:国际儿童APL联盟研究结果
国际儿童APL联盟(ICC-APL-01)试验纳入258例分子学/细胞遗传学确诊的儿童及青少年APL患者,按基线白细胞计数分层为标危和高危组,均接受全反式维甲酸(ATRA)联合3剂去甲氧柔红霉素诱导,标危组2个、高危组3个巩固疗程,所有患者接受2年低剂量化疗联合ATRA维持治疗。标危和高危组柔红霉素当量蒽环类累积剂量分别为355 mg/m2和405 mg/m2,低于既往研究。血液学缓解率97%,8例在诊断后前2周死于颅内出血;全队列5年总生存率和无事件生存率分别为94.6%和79.9%,标危组为98.4%和89.4%,高危组为84.3%和74.2%(P=.002和P=.043)。
要点
- 标危和高危组柔红霉素当量蒽环类累积剂量分别为355 mg/m2和405 mg/m2,低于既往研究。
- 全队列5年总生存率94.6%、无事件生存率79.9%;标危组分别为98.4%和89.4%,高危组分别为84.3%和74.2%。
- 血液学缓解率97%,8例在诊断后前2周死于颅内出血。
核心结论
- 延长ATRA使用联合风险适应巩固治疗可在儿童APL中实现高治愈率并限制蒽环类暴露。
研究设计与样本
- 国际儿童APL联盟(ICC-APL-01)试验,纳入258例分子学/细胞遗传学确诊的儿童及青少年APL患者。
- 按基线白细胞计数分层:标危(<10 × 109/L)和高危(≥10 × 109/L)。
- 两组均接受ATRA联合3剂去甲氧柔红霉素诱导;标危组2个、高危组3个巩固疗程;所有患者接受2年低剂量化疗联合ATRA维持治疗。
- 试验注册号:EudractCT 2008-002311-40。
主要发现
- 标危和高危组柔红霉素当量蒽环类累积剂量分别为355 mg/m2和405 mg/m2,低于既往研究。
- 血液学缓解率97%;8例在诊断后前2周死于颅内出血。
- 全队列5年总生存率94.6%、无事件生存率79.9%。
- 标危组5年总生存率98.4%、无事件生存率89.4%;高危组分别为84.3%和74.2%(P=.002和P=.043)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric acute promyelocytic leukemia (APL) can be cured with all-trans retinoic acid (ATRA) and anthracycline. However, most published trials have employed high cumulative doses of anthracyclines. Here, we report the outcome of newly diagnosed APL patients enrolled in the International Consortium for Childhood APL (ICC-APL-01) trial, which reduced anthracycline exposure but extended that of ATRA. The study recruited 258 children/adolescents with molecularly/cytogenetically proven APL. Patients were stratified into standard-risk (SR) and high-risk (HR) groups according to baseline white blood cell counts (<10 × 109/L or ≥10 × 109/L); both groups received identical induction treatment with ATRA and 3 doses of idarubicin. Two or 3 blocks of consolidation therapy were administered to SR and HR patients, respectively, while maintenance therapy with low-dose chemotherapy and ATRA cycles was given to all patients for 2 years. The cumulative dose of daunorubicin equivalent anthracyclines in SR and HR patients was lower than that of previous studies (355 mg/m2 and 405 mg/m2, respectively). Hematologic remission was obtained in 97% of patients; 8 children died of intracranial hemorrhage in the first 2 weeks following diagnosis. Five-year overall and event-free survival for the whole cohort were 94.6% and 79.9%, respectively; they were 98.4% and 89.4% in SR patients and 84.3% and 74.2% in HR patients (P = .002 and P = .043, respectively). These data demonstrate that extended use of ATRA coupled to a risk-adapted consolidation can achieve high cure rates in childhood APL and limit anthracycline exposure. The trial was registered at www.clinicaltrials.gov as EudractCT 2008-002311-40.
引用
- Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018. PMID: 29789356. doi:10.1182/blood-2018-03-836528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。